Qbrexza Cloth
NDC Package 69489-411-05
Package Information
Qbrexza (glycopyrronium) cloths is this form of glycopyrronium is used to treat excessive sweating from your underarms. This formulation utilizes a cloth delivery system. Marketed by Journey Medical Corporation, this product is identified by NDC 69489-411 and is authorized under FDA application NDA210361.
Identification & Billing
- RxCUI: 2054118 - glycopyrronium 2.4 % Medicated Cloth
- RxCUI: 2054118 - glycopyrronium 24 MG/ML Medicated Pad
- RxCUI: 2054120 - Qbrexza 2.4 % Medicated Cloth
- RxCUI: 2054120 - glycopyrronium 24 MG/ML Medicated Pad [Qbrexza]
- RxCUI: 2054120 - Qbrexza 24 MG/ML Medicated Pad
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 69489 - Journey Medical Corporation
- 69489-411 - Qbrexza
- 69489-411-05 - 5 POUCH in 1 CARTON / 2.8 g in 1 POUCH (69489-411-51)
- 69489-411 - Qbrexza
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (69489-411). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 69489-411-05 identifies a specific commercial package of 5 pouch in 1 carton / 2.8 g in 1 pouch (69489-411-51) of Qbrexza, a human prescription drug labeled by Journey Medical Corporation. This cloth is formulated for topical use and contains glycopyrronium tosylate as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Journey Medical Corporation on June 28, 2018. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
This form of glycopyrronium is used to treat excessive sweating from your underarms. The drug solution is on a pre-moistened cloth for application to the skin. It works on the sweat glands to reduce sweating. Glycopyrronium belongs to a class of drugs known as anticholinergics.
How is this Journey Medical Corporation product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 69489041105. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.